Resmetirom and GLP-1 agonists for MASH: complementary rather than exclusive Resmetirom exhibits promising results as a specific treatment for MASH
An interim analysis of the semaglutide phase 3 trial confirmed its efficacy in improving steatohepatitis and demonstrated its potential to improve fibrosis
Similarly, models with significant kidney or liver dysfunction are generally unsuitable, as impaired peptide clearance may heighten the risk of adverse effects
Indeed, the history of anti-obesity medications has been marked by several failures due to serious adverse events, such as suicidality, observed only after their usage had become extensive 221,234 a well-known example being the one that led to the withdrawal of the endocannabinoid inverse agonist, rimonabant 235
Symptoms can include nausea, vomiting, abdominal bloating and pain, severe malnutrition, and alterations in blood sugar levels, which can be particularly dangerous for individuals with diabetes
What is Methylcobalamin